A placebo-controlled clinical study of AXO-AAV-OPMD for oculopharyngeal muscular dystrophy (OPMD)
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs AXO-AAV-OPMD (Primary)
- Indications Oculopharyngeal muscular dystrophy
- Focus Adverse reactions
- Sponsors Axovant Gene Therapies
- 03 Jan 2019 According to an Axovant Sciences media release, initiation of clinical program is expected in the second half of 2019.
- 11 Jul 2018 New trial record
- 08 Jul 2018 According to an Axovant Sciences media release, the company expects to start this trial in 2019.